Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Valley National Bancorp Common Stock (VLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Valley National Bancorp Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while Valley National Bancorp Common Stock trades at $12.42 (market cap $6.86B). The key difference: Kymera Therapeutics Inc. Common Stock is the larger of the two by market cap, and Valley National Bancorp Common Stock pays a 3.55% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Valley National Bancorp Common Stock for 6 Days on average.
| KYMR | VLY | |
|---|---|---|
Market Cap | $8.88B | $6.86B |
Volume | 1,028,790 | 6,537,186 |
Sector | Health | Financials |
52-Week High | $127.31 | $15.19 |
52-Week Low | $55.80 | $9.72 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $8.27B | $9.35B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Valley National Bancorp (VLY) trades at $12.53, down 0.87% with a bearish technical outlook. The stock shows strong fundamentals with a P/E of 10.61 and P/B of 0.91, indicating potential undervaluation. Recent earnings show mixed results with Q2 2026 missing estimates, but revenue growth remains solid at $2.2B for 2026. The company is actively expanding through acquisitions including Bluevine and Providence Financial to strengthen its deposit base and Chicago market presence.
Analyst consensus remains bullish with 62% buy ratings and a $16.50 price target, suggesting 32% upside potential. Key risks include integration challenges from recent acquisitions and higher operating expenses impacting margins. The upcoming Q3 2026 earnings report on October 22 will be crucial for validating growth trajectory amid current bearish technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Valley National Bancorp Common Stock
Valley National Bancorp is a financial holding company whose main subsidiary is Valley National Bank. It provides commercial, retail, trust, and investment services across several U.S. states.
Read more on VLY →
